The US Food and Drug Administration (FDA) is dropping its complaint against Whoop Inc. concerning the company’s blood-pressure tracking tool. According to multiple reports, the FDA previously took issue with the feature and had asked Whoop to disable it. After the company made changes to the blood-pressure functionality, the FDA reverses course and indicates it will not pursue additional enforcement. One outlet reports that the FDA communicates that it will not take further enforcement action following Whoop’s tweaks to the feature, while another describes the FDA formally dropping the complaint altogether. The reports characterize the outcome as an about-face from the FDA’s earlier position. The agencies’ shift suggests the FDA’s concerns may have been addressed through modifications to how the tool works or how it is presented. The coverage does not add new technical details in the cited summaries beyond the sequence of events: an initial FDA request to disable the tool, followed by later compliance-related changes by Whoop and the subsequent decision to end enforcement.